drugset / Trial / NCT00751348
Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136
RandomizedParallel-groupOpen-labelPrevention
Summary
This Phase 3b study is being conducted for the purpose of registration of the GSK208136 vaccine in Korea.
Timeline
- Start
- 2008-10-01
- Primary completion
- 2010-05-27
- Completion
- 2010-05-27
Publications
- Background Sung-Ho Cha et al. Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella (MMRV) vaccine: an open-labeled, randomized trial in healthy Korean children. Abstract presented at the Fall Meeting of Korean Vaccine Society (KVS). Seoul, Korea, 31 August 2013.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Priorix-Tetra | Vaccine | — | Subcutaneous |
| Comparator | PriorixTM | Vaccine | — | Subcutaneous |
| Comparator | VarilrixTM | Vaccine | — | Subcutaneous |